Sofosbuvir/daclatasvir combination could be produced for $200 per hepatitis C cure
Grazoprevir/elbasvir cures more than 90% of people with HIV/HCV co-infection
United States faces biggest burden of hepatitis C treatment costs before 2020
High HCV cure rate demonstrated for people retreated after failure of short course direct-acting antiviral therapy
Clinical impact of effective HCV DAAs: referrals for liver transplant drop after their introduction
Study reveals potential challenges for scaling up of HCV therapy in UK
Liver fibrosis improves after successful treatment for hepatitis C
Daclatasvir plus sofosbuvir works well for people with genotype 3 hepatitis C and advanced liver disease in real-world clinical practice
Daclatasvir and sofosbuvir with ribavirin cures 90% of people with genotype 3 hepatitis C
